股票代码：603351 证券简称：威尔药业 公告编号：2025-007 南京威尔药业集团股份有限公司 关于2024年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 每10股派发现金红利 4.00 元（含税）。 ● 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期将 在权益分派实施公告中明确。 ● 在实施权益分派的股权登记日前公司总股本发生变动的，公司拟维持每股分 配比例不变，相应调整分配总额，并将另行公告具体调整情况。 ● 本次利润分配方案不触及《上海证券交易所股票上市规则》第9.8.1条第一款 第（八）项规定的可能被实施其他风险警示的情形。 一、利润分配方案内容 经信永中和会计师事务所（特殊普通合伙）审计，截至2024年 12月 31日,公司 母公司报表中期末未分配利润为 56,120.71 万元。经公司第三届董事会第十一次会议 决议，公司2024年度拟以实施权益分派股权登记日登记的总股本为基数分配利润。 本次利润分配方案如下： 公司拟向全体股东每10股派发现金红利 ...

南京威尔药业集团股份有限公司（以下简称"公司"）股票于 2025 年 4 月 17 日、 4 月 18 日、4 月 21 日连续 3 个交易日内日收盘价格涨幅偏离值累计超过 20%，根据 《上海证券交易所交易规则》的有关规定，已构成股票交易异常波动。 证券代码：603351 证券简称：威尔药业 公告编号：2025-016 南京威尔药业集团股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、股票交易异常波动的具体情况 4、未发现公司董事、监事、高级管理人员、控股股东及实际控制人在股票交易 异常波动期间买卖公司股票。 三、相关风险提示 公司股票于 2025 年 4 月 17 日、4 月 18 日、4 月 21 日连续 3 个交易日内日收盘 价格涨幅偏离值累计超过20%，已构成股票交易异常波动，公司郑重提醒广大投资者 注意二级市场交易风险，理性决策，审慎投资。公司有关信息以在上海证券交易所网 站（www.sse.com.cn）及公司指定信息披露媒体《上海证券报》《证券时报》刊登的 公告为准。 四、 ...

南京 威 尔 药 业 集 团 股 份 有 限 公 司 2024 年度 审计报告 | 索引 | 喷型 | | --- | --- | | 审计报告 | 1-5 | | 公司财务报表 | | | 合并资产负债表 | 1-2 | | 母公司资产负债表 | 3-4 | | 合并利润表 | 5 | | 母公司利润表 | 6 | | 合并现金流量表 | 7 | | 母公司现金流量表 | 8 | | 合并股东权益变动表 | 9-10 | | 母公司股东权益变动表 | 11-12 | | 财务报表附注 | 13-95 | 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（hm·//arcrewfolly | A | | | | --- | --- | --- | | 号富华大厦 A 座 9 层 | | telephone: +86 (010) 6554 2288 | | 9/F. Block A. Fu Hua Mansion, No.8, Chaoyangmen Beidajie, ShineWing | 专真: | +86 (010) 6554 / 190 | | Donacheng District. Beij ...

南京威尔药业集团股份有限公司 2024 年 12 月 31 日 索引 内部控制审计报告 喷ษ 1-2 内部控制审计报告 XYZH/2025NJAA1B0003 南京威尔药业集团股份有限公司 南京威尔药业集团股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计 了南京威尔药业集团股份有限公司 ( 以下简称威尔药业 ) 2024 年 12 月 31 日财务报告内 部控制的有效性。 您可使用手机"扫一扫"或进入"注册会计师行业第一位带来会（http://www.blogs.com/ 一、 企业对内部控制的责任 re 信永中和会计师事务所 北京市东城区朝阳门北大街 母系由话 8 号宫 长 大 圈 A 麻 9 层 QIF RInck A Fil Hua No 8 Chaovangmen Be Donachena District 100027 P R China 按照《企业内部控制基本规范》 、《企业内部控制应用指引》 、《企业内部控制评 价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是威尔药业董事会的 责任。 二、 注册会计师的责任 我们认为,威尔药业于 202 ...

南京威尔药业集团股份有限公司 2024 年度独立董事述职报告 作为南京威尔药业集团股份有限公司（以下简称"公司"）的第三届董事会独 立董事，本人严格按照《公司法》《上市公司治理准则》《上市公司独立董事管 理办法》等法律法规以及《公司章程》《公司独立董事工作制度》等规定和要求， 切实履行忠实勤勉义务，充分发挥独立董事作用。现将本人 2024 年度履职情况 报告如下： 管国锋：1962 年出生，中国国籍，无境外永久居留权，博士研究生学历。 1984 年 7 月至 2020 年 11 月，历任南京工业大学化工学院系主任及副院长、继 续教育学院院长、教务处处长、研究生院常务副院长、科研部部长。2019 年 5 月至今，担任南京工业大学西太湖产业学院院长，兼任南工大西太湖(常州)科 技有限公司执行董事、总经理。2023 年 5 月至今，担任公司独立董事。 经自查，本人符合中国证监会《上市公司独立董事管理办法》《上海证券交 易所上市公司自律监管指引第1 号——规范运作》中关于独立董事独立性的要求， 不存在影响独立性的情况。 2024 年公司共计召开四次董事会，一次股东大会。本人出席董事会和股东大 会的情况如下： | | ...

南京威尔药业集团股份有限公司 2024 年度独立董事述职报告 作为南京威尔药业集团股份有限公司（以下简称"公司"）的第三届董事会独 立董事，本人严格按照《公司法》《上市公司治理准则》《上市公司独立董事管 理办法》等法律法规以及《公司章程》《公司独立董事工作制度》等规定和要求， 切实履行忠实勤勉义务，充分发挥独立董事作用。现将本人 2024 年度履职情况 报告如下： 魏明：1988年出生，中国国籍，无境外永久居留权，硕士研究生学历。 2014 年 7 月至 2022 年 12 月，担任江苏华昕律师事务所律师。2023 年 1 月至 2023 年 9 月，担任江苏中盟律师事务所律师。2023 年 10 月至今，担任江苏达 岸律师事务所律师、合伙人。2023 年 5 月至今，担任公司独立董事。 经自查，本人符合中国证监会《上市公司独立董事管理办法》《上海证券交 易所上市公司自律监管指引第1 号——规范运作》中关于独立董事独立性的要求， 不存在影响独立性的情况。 2024 年公司共计召开四次董事会， 一次股东大会。本人出席董事会和股东大 会的情况如下： 南京威尔药业集团股份有限公司 2024 年度独立董事述职报告 积 ...

南京威尔药业集团股份有限公司 2024 年度独立董事述职报告 作为南京威尔药业集团股份有限公司（以下简称"公司"）的第三届董事会独 立董事，本人严格按照《公司法》《上市公司治理准则》《上市公司独立董事管 理办法》等法律法规以及《公司章程》《公司独立董事工作制度》等规定和要求， 切实履行忠实勤勉义务，充分发挥独立董事作用。现将本人 2024 年度履职情况 报告如下： 管亚梅：1970 年出生，中国国籍，无境外永久居留权，博士研究生学历。 1993 年 8 月至今就职于南京财经大学，目前担任南京财经大学会计学院教授， 兼任苏州海陆重工股份有限公司独立董事。2023 年 5 月至今，担任公司独立董 事。 经自查，本人符合中国证监会《上市公司独立董事管理办法》《上海证券交 易所上市公司自律监管指引第1 号——规范运作》中关于独立董事独立性的要求， 不存在影响独立性的情况。 报告期内，本人积极参与董事会决策并对所议事项发表明确意见；对公司与 其控股股东、实际控制人、董事、高级管理人员之间的潜在重大利益冲突事项进 行监督，促使董事会决策符合公司整体利益，保护中小股东合法权益；对公司经 营发展提供专业、客观的建议，促进提升 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 349.73 million, representing a 6.03% increase compared to CNY 329.83 million in the same period last year[4]. - Net profit attributable to shareholders was CNY 36.59 million, up 5.73% from CNY 34.60 million year-on-year[4]. - Total operating revenue for Q1 2025 reached ¥349,725,188.55, an increase of 6.4% compared to ¥329,832,361.62 in Q1 2024[17]. - Net profit for Q1 2025 was ¥35,766,178.54, representing a 6.7% increase from ¥33,516,432.21 in Q1 2024[18]. - Earnings per share for Q1 2025 were ¥0.27, compared to ¥0.26 in Q1 2024, indicating a slight improvement[18]. Cash Flow - The net cash flow from operating activities decreased by 24.93% to CNY 22.21 million, down from CNY 29.59 million in the previous year[4]. - In Q1 2025, the cash inflow from operating activities was CNY 268,677,131.12, a decrease of 1.18% compared to CNY 273,321,097.29 in Q1 2024[21]. - The net cash flow from operating activities in Q1 2025 was CNY 22,211,455.90, down 25.06% from CNY 29,588,625.58 in Q1 2024[21]. - The cash outflow for investing activities in Q1 2025 totaled CNY 50,525,198.83, significantly higher than CNY 14,949,433.43 in Q1 2024[22]. - The net cash flow from investing activities was -CNY 49,625,198.83 in Q1 2025, compared to -CNY 12,034,860.57 in Q1 2024, indicating increased investment expenditures[22]. - Cash inflow from financing activities in Q1 2025 was CNY 121,000,000.00, up 51.25% from CNY 80,000,000.00 in Q1 2024[22]. - The net cash flow from financing activities improved to CNY 23,604,271.83 in Q1 2025, compared to a negative CNY 28,831,323.60 in Q1 2024[22]. - The ending cash and cash equivalents balance as of Q1 2025 was CNY 243,388,554.83, an increase from CNY 146,935,955.31 in Q1 2024[22]. Assets and Liabilities - Total assets at the end of Q1 2025 reached CNY 2.42 billion, reflecting a 1.81% increase from CNY 2.38 billion at the end of the previous year[6]. - Total assets as of the end of the reporting period were ¥2,423,991,651.70, compared to ¥2,380,913,919.67 at the end of the previous period, an increase of 1.8%[14]. - Total liabilities amounted to ¥679,504,636.68, slightly up from ¥672,715,662.08, reflecting a 1.2% increase[14]. - Non-current assets totaled ¥1,688,996,630.37, an increase from ¥1,663,708,867.64, indicating a growth of 1.5%[14]. - The company reported a decrease in accounts payable to ¥91,037,461.15 from ¥98,757,278.22, a reduction of 7.3%[14]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 5,012, with no preferred shareholders[9]. - The top ten shareholders collectively hold 70.12% of the company's shares, with the largest shareholder, Wu Renrong, owning 13.68%[9]. Expenses - Total operating costs for Q1 2025 were ¥307,861,914.39, up from ¥290,059,404.32 in Q1 2024, reflecting a year-over-year increase of 6.3%[17]. - Research and development expenses increased to ¥18,198,856.61 in Q1 2025, up from ¥15,768,635.95 in Q1 2024, marking a growth of 15.4%[17]. - The cash outflow for employee compensation in Q1 2025 was CNY 55,445,080.19, an increase of 15.06% from CNY 48,087,072.98 in Q1 2024[21]. - The company reported a decrease in tax payments, with CNY 14,492,378.79 in Q1 2025 compared to CNY 19,139,293.68 in Q1 2024, reflecting a 24.06% reduction[21]. Other Financial Metrics - The weighted average return on equity was 2.13%, a slight decrease of 0.03 percentage points from 2.16% in the previous year[4]. - The company reported a significant increase in prepayments, which rose by 36.96% due to higher raw material prepayments[7]. - Other receivables decreased by 35.26%, primarily due to a reduction in export tax refunds[7]. - Long-term borrowings increased by 57.14%, attributed to new medium to long-term bank loans[7].

Financial Performance - In 2024, the company achieved a net profit attributable to shareholders of 146.42 million yuan, an increase of 30.50% compared to 2023[5]. - The total operating revenue for 2024 was 1.30 billion yuan, reflecting a year-on-year growth of 12.19%[21]. - The net cash flow from operating activities reached 221.79 million yuan, up 84.45% from the previous year[21]. - The company's total assets as of December 31, 2024, amounted to 2.38 billion yuan, a 4.48% increase from the end of 2023[21]. - The basic earnings per share for 2024 were 1.08 yuan, representing a 30.12% increase compared to 2023[22]. - The weighted average return on equity rose to 8.94%, an increase of 1.55 percentage points from the previous year[22]. - The cumulative undistributed profits as of December 31, 2024, were 555.70 million yuan[5]. - The company reported a net profit of 30.77 million yuan for the parent company in 2024, with cumulative undistributed profits of 561.21 million yuan[5]. Revenue and Sales Growth - The company achieved operating revenue of 1,296.75 million RMB in 2024, representing a year-on-year growth of 12.19%[29]. - Sales volume of synthetic lubricating base oil grew by 13.17%, with sales revenue increasing by 9.53%[30]. - The sales volume of pharmaceutical excipients increased by 19.23%, and sales revenue rose by 15.44%[31]. - Revenue from synthetic lubricating base oil was ¥887,290,773.05, with a gross margin of 21.02%, reflecting an increase of 0.96 percentage points[58]. - The pharmaceutical excipients segment generated ¥336,150,944.64 in revenue, achieving a gross margin of 49.58%, up by 2.13 percentage points[58]. Research and Development - R&D expenses amounted to 71.56 million RMB, up 28.60%, accounting for 5.52% of operating revenue[33]. - The company has established multiple national and provincial-level R&D platforms, enhancing its innovation capabilities[46]. - The company is committed to innovation-driven development, focusing on process technology improvements and establishing a leading green pharmaceutical materials production base[38]. - The company focuses on developing high-safety, multifunctional pharmaceutical excipients and high-performance synthetic lubricating base oils, providing quality solutions and technical services to clients[43]. - The company has implemented a comprehensive procurement management system to optimize its supply chain and production planning[89]. Strategic Initiatives and Acquisitions - The company successfully acquired Shengwei New Materials, enhancing its strategic resource reserves[34]. - The company initiated trial production of a 5800t/a POE ester expansion project, expected to provide additional capacity for lubricating base oil[34]. - The company acquired a subsidiary, Nanjing Shengwei New Materials Technology Co., Ltd., with a registered capital of 20 million RMB, expanding its capabilities in new materials[106]. Market Trends and Industry Insights - The lubricating oil industry is experiencing diversification in application fields, driven by national policies promoting new quality productivity and high-quality development[39]. - The penetration rate of new energy vehicles reached 40.9% in 2024, indicating stable growth and expanding market share for low-viscosity synthetic ester products[41]. - The market for household air conditioning is recovering, with a V-shaped trend in sales, leading to increased demand for compatible refrigerants[41]. - In the pharmaceutical excipients industry, the government has introduced supportive policies to promote high-quality development, with a focus on smart manufacturing and high-end pharmaceutical excipients[36]. Risk Management and Compliance - The company has outlined potential risks in its management discussion and analysis section, emphasizing the importance of investor awareness[7]. - The company faces market risks due to increasing competition and regulatory changes in the pharmaceutical excipients industry[119]. - The company faces risks related to the supply and price volatility of key raw materials such as ethylene oxide and propylene oxide, which are crucial for production and closely tied to oil prices[123]. - Environmental protection regulations are becoming stricter, potentially increasing operational costs and impacting the company's financial performance if compliance is not maintained[123]. Corporate Governance and Management - The company has established a governance structure compliant with relevant laws and regulations, ensuring proper operation of the board and shareholder meetings[126]. - The company has approved various resolutions at the 2023 annual general meeting, including the 2023 financial report and profit distribution plan[126]. - The management team consists of experienced professionals from the industry, enhancing operational efficiency and strategic direction[52]. - The company has established specialized committees within the board, including the Audit Committee and the Compensation and Assessment Committee[138]. Employee and Shareholder Engagement - The company has implemented a structured compensation management system to enhance employee motivation and ensure sustainable development[145]. - The company emphasizes talent development through annual training plans and a certified internal trainer team to improve employee skills and management capabilities[146]. - The company plans to distribute a cash dividend of 4.00 RMB per 10 shares, totaling 54,175,652.80 RMB, which represents 37.00% of the net profit attributable to ordinary shareholders[151]. Environmental Responsibility - The company invested 6.9248 million yuan in environmental protection during the reporting period[159]. - Weir Biotech has a waste gas treatment capacity of 3000 m³/h for various pollutants, and all treatment facilities are operating normally[161]. - Both subsidiaries have obtained ISO 14001 environmental management system certification, ensuring effective environmental management practices[169]. - The company emphasizes sustainable development by optimizing production processes to reduce energy consumption and environmental impact[169].

证券代码：603351 证券简称：威尔药业 公告编号：2025-013 二、主要产品和原材料的价格变动情况 （一）主要产品销售价格变动情况 单位：元/吨（不含税） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 南京威尔药业集团股份有限公司（以下简称"公司"）主营业务为药用辅料及合 成润滑基础油产品的研发、生产和销售。根据上海证券交易所发布的《上市公司行 业信息披露指引第十四号－化工》等文件要求，现将公司 2025 年第一季度主要经营 数据公告如下： | 主要产品 | 2025 年 1-3 月 | 2025 年 | 1-3 月 | 2025 年 | 1-3 月 | | --- | --- | --- | --- | --- | --- | | | 生产量（吨） | | 销售量（吨） | 销售收入（万元） | | | 1、合成润滑基础油 | 15,781.08 | | 15,273.36 | | 24,264.46 | | 其中：机械类 | 10,706.87 | | 10,503.41 | | 18,637.12 | | 非机 ...